The ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 pipeline drugs market research report outlays comprehensive information on the ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Hematological Disorders which include the indications Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Systemic Lupus Erythematosus, Autoimmune Disorders, Primary Systemic Amyloidosis, Unspecified Metabolic Disorders, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), and Antiphospholipid Syndrome. It also reviews key players involved in ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 targeted therapeutics development with respective active and dormant or discontinued products.
The ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 pipeline targets constitutes close to 90 molecules. Out of which, approximately 72 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 2, 6, 13, 2, 4, 36, and 6 respectively. Similarly, the universities portfolio in Phase II, Phase I, Phase 0, Preclinical, and Discovery comprises 6, 5, 2, 4, and 1 molecule.
ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 overview
ADP ribosyl cyclase/cyclic ADP ribose hydrolase 1 is a non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes cyclic adenosine 5′-diphosphate-ribose, an intracellular calcium ion mobilizing messenger. This protein has an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a C-terminal extracellular region with four N-glycosylation sites. It is used as a prognostic marker for patients with chronic lymphocytic leukemia.
For a complete picture of ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
